The Human Data Era - The Role of Human Diversity in Progressing Precision Medicine

By understanding disease risk through the information found in a person’s genome, scientists can develop more effective therapeutics and clinicians can treat their patients more effectively.

In this episode, we talk to Kári Stefánsson, founder and CEO of deCODE Genetics, a Reykjavik-based biopharmaceutical company that collects and analyzes genealogical, medical, and genomic data at a national scale in order to identify variants that cause disease. We discuss his pioneering work in population-scale genetics, its applications in precision medicine and the healthcare system, and the difficult questions that access to these data raise.

To dive further into this topic, please join Amgen scientists at the Human Data Era Q&A webinar discussion on November 16, 2022. Register for the event here.

 

Welcome to The Human Data Era, a special edition podcast series produced by The Scientist’s Creative Services Team.

This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines.

 

By studying human genetics, scientists discovered mechanisms that, when defective, cause disease. While this type of data is powerful, additional information can provide more insight on the human condition. Researchers and clinicians can now go beyond genetics, combining proteomics, metabolomics, transcriptomics, and environmental factors into a broad category of human data. In this series, Ray Deshaies, senior vice president of Global Research at Amgen, explores the potential of human data and the important transition scientists and clinicians are making to incorporate this wealth of information into drug research and development.